首页 | 本学科首页   官方微博 | 高级检索  
     


CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia
Authors:Lidia?Ciszak  author-information"  >  author-information__contact u-icon-before"  >  mailto:ciszak@iitd.pan.wroc.pl"   title="  ciszak@iitd.pan.wroc.pl"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author,Irena?Frydecka,Dariusz?Wolowiec,Aleksandra?Szteblich,Agata?Kosmaczewska
Affiliation:1.Laboratory of Immunopathology, Department of Experimental Therapy, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,Polish Academy of Sciences,Wroc?aw,Poland;2.Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation,Wroclaw Medical University,Wroc?aw,Poland
Abstract:Previously, we showed that cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is overexpressed in chronic lymphocytic leukaemia (CLL) and its expression is correlated with the expression of the major regulators of G1 phase progression: cyclins D2 and D3, and cyclin-dependent kinase inhibitory protein 1 (p27 KIP1 ). In the present study, we blocked CTLA-4 on the surface of both CLL cells and normal B lymphocytes to investigate the impact of CTLA-4 on the expression of the mentioned G1 phase regulators. We found that in CLL patients and in healthy individuals, the median proportions of cyclin D2-positive cells as well as cyclin D3+ cells significantly decreased following CTLA-4 blockade. Moreover, CTLA-4 blockade led to an increase in the median frequencies of p27 KIP1 -positive cells, although this increase was marked only in CLL patients. Our study showed that CTLA-4 affects the expression of the key regulators of G1 phase progression in CLL cells as well as in normal B lymphocytes and may contribute to a better understanding of the role of CTLA-4 in the regulation of G1 phase progression.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号